• М.Ю. Дельва Полтавський державний медичний університет, м. Полтава, Україна
  • І.І. Дельва Полтавський державний медичний університет, м. Полтава, Україна
  • В.А. Пінчук Полтавський державний медичний університет, м. Полтава, Україна
  • Г.Я. Силенко Полтавський державний медичний університет, м. Полтава, Україна
  • А.М. Кривчун Полтавський державний медичний університет, м. Полтава, Україна
Keywords: medication overuse headache, chronic tension type headache, risk factors.


Introduction. A study of medication overuse headache (MOH) can define the risk group for MOH in patients with primary headaches. The aim of the research is to study the socio-demographic, clinical and pharmacotherapeutic characteristics of patients with MOH and chronic tension-type headache (CTTH). Material and methods. We examined 28 patients with MOH in combination with CTTH and 34 patients with CTTH. MOH and CTTH were diagnosed according to the International Classification of Headache Disorders 3rd revision. Anxiety and depressive signs were assessed by the Hospital Anxiety and Depression Scale; abdominal obesity was determined using waist circumference. Quantitative values were presented as the median and the interquartile range. Quantitative samples were analyzed according to Mann-Whitney U-test, qualitative samples - according to Fisher's exact test. Differences at p <0.05 were considered significant. Results. Patients with MOH and CTTH had the following characteristics: female gender - 79%, age - 41.0 (33.0-49.5) years, familyless state - 54%, higher education - 25%, employment - 46%, smoking - 43%, anxiety signs - 71%, depressive signs - 75%, cervicalgia - 36%, lower back pain - 61%, arterial hypertension - 21%, diabetes mellitus - 7%, abdominal obesity - 46%, mild traumatic brain injury - 43%, headache intensity - 5.0 (4.0-6.3) points on a visual analog scale, duration of headache attacks - 7.0 (5.0-8.3) hours, age of CTTH onset - 31,5 (23,0-41,0) years, duration of CTTH - 9.0 (6,8-10,3) years, duration of MOH – 15.5 (8.3-20.8) months. Patients with MOH and CTTH compared to patients with CTTH were significantly younger, had a history of traumatic brain injury, had significantly more headache days per month. Patients with MOH and CTTH overused combined analgesics (47%), nonsteroidal anti-inflammatory drugs (32%), triptans with analgesics (21%). Abortive medications had been used on 23.0 (18.0-28.5) days a month, in form of 32.0 (27.3 -41.8) doses a month.


Download data is not yet available.


1. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nature Reviews Neurology. 2016 Oct;12(10):575.
2. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. The Lancet Neurology. 2010 Apr 1;9(4):391-401.
3. Delva M, Delva I. Analysis of primary headaches management in poltava regions. Wiad Lek. 2021 Jan 1;74(1):118-21.
4. Olesen J. Headache Classification Committee of the International Headache Society (IHS) the international classification of headache disorders, asbtracts. Cephalalgia. 2018 Jan 1;38(1):1-211.
5. Westergaard ML, Hansen EH, Glümer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014 May;34(6):409-25.
6. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, Coggeshall M. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The lancet. 2016 Oct 8;388(10053):1545-602.
7. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri‐Minet M, Rastenyte D, Ruiz de la Torre E. The cost of headache disorders in Europe: the Eurolight project. European journal of neurology. 2012 May;19(5):703-11.
8. Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bortel LM, Van Tongelen I, De Bolle L, Remon JP, Boussery K. Self‐medication of regular headache: a community pharmacy‐based survey. European journal of neurology. 2012 Aug;19(8):1093-9.
9. Kristoffersen ES, Grande RB, Aaseth K, Lundqvist C, Russell MB. Management of primary chronic headache in the general population: the Akershus study of chronic headache. The journal of headache and pain. 2012 Mar 1;13(2):113-20.
10. Jonsson P, Linde M, Hensing G, Hedenrud T. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. The journal of headache and pain. 2012 Jun;13(4):281-90.
11. Дельва М.Ю., Дельва І.І. Соціально-демографічні та коморбідні характеристики пацієнтів з хронічним головним болем напруги. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії. 2021 Mar 21;21(1):16-20.
12. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica scandinavica. 1983 Jun;67(6):361-70.
13. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health Organization; 1999.
14. Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011 Jul;31(9):1015-22.
15. Atasoy HT, Unal AE, Atasoy N, Emre U, Sumer M. Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache: The Journal of Head and Face Pain. 2005 Jan;45(1):25-31.
16. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 2012 Jan 1;153(1):56-61.
17. Couch JR, Lipton RB, Stewart WF, Scher AI. Head or neck injury increases the risk of chronic daily headache: a population-based study. Neurology 2007; 69: 1169–77.
18. Kjeldgaard D, Forchhammer H, Teasdale T, Jensen RH. Chronic post-traumatic headache after mild head injury: a descriptive study. Cephalalgia. 2014 Mar;34(3):191-200.
19. Westergaard ML, Glümer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. PAIN®. 2014 Oct 1;155(10):2005-13.
20. Shand B, Goicochea MT, Valenzuela R, Fadic R, Jensen R, Tassorelli C, Nappi G. Clinical and demographical characteristics of patients with medication overuse headache in Argentina and Chile: analysis of the Latin American Section of COMOESTAS Project. The Journal of Headache and Pain. 2015 Dec;16(1):1-4.
21. Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Goicochea MT, Shand B, Fadic R, Spadafora S. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. The journal of headache and pain. 2016 Dec;17(1):1-12.
22. Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology. 2004 Apr 27;62(8):1338-42.
How to Cite
Дельва, М., Дельва, І., Пінчук, В., Силенко, Г., & Кривчун, А. (2021). СОЦІАЛЬНО-ДЕМОГРАФІЧНІ ТА КЛІНІЧНІ ХАРАКТЕРИСТИКИ ПАЦІЄНТІВ З АБУЗУСНИМ ГОЛОВНИМ БОЛЕМ В ПОЄДНАНІ З ХРОНІЧНИМ ГОЛОВНИМ БОЛЕМ НАПРУГИ. The Medical and Ecological Problems, 25(3-4), 3-7. https://doi.org/10.31718/mep.2021.25.3-4.01